Nonalkolik Steatohepatitli Ratlarda N-Asetilsistein, Rosiglitazon ve Etodolak’ın Tedavi Edici Etkilerinin Değerlendirilmesi
Amaç: Bu çalışmanın amacı, ratlarda yüksek yağlı diyet (HFD) ile indüklenen Nonalkolik steatohepatitin (NASH) deneysel bir modelinde Nasetilsistein (NAC), Rosiglitazon (RSG) ve Etodolak (ETD) terapötik etkilerini ve peroxisome proliferators-activated receptors-α (PPARα) ile etkileşimlerini değerlendirmektir. Gereç ve Yöntem: Sprague-Dawley erkek sıçanlar rastgele beş gruba ayrıldı: Grup 1 Standart diyet (SD) ile beslenen sıçanlar; Grup 2 HFD ile beslenen sıçanlar; Grup 3 HFD ile beslenen ve sonrasında 4 hafta boyunca NAC ile tedavi edilen sıçanlar; Grup 4 HFD ile beslenen ve sonrasında 4 hafta boyunca RSG ile tedavi edilen sıçanlar; Grup 5 yirmi hafta boyunca HFD ile beslenen ve sonrasında 4 hafta boyunca ETD ile tedavi edilen sıçanlar. Tüm grupların karaciğer malonil dialdehit (MDA), karaciğer PPAR-α expression değerlerini değerlendirdik. Bulgular: Çalışmamızda karaciğer PPAR-α expression parametresinde ETD grubunda HFD grubuna göre anlamlı bir artma olduğu, karaciğer MDA parametresinde ETD grubunda HFD grubuna göre anlamlı bir azalma olduğu görüldü. Çalışmamızda karaciğer PPAR-α expression parametresinde NAC grubunda HFD grubuna göre anlamlı bir azalma olduğu, karaciğer MDA parametresinde NAC grubunda HFD grubuna göre anlamlı bir azalma olduğu görüldü. Sonuç: Bu bulgular, ETD’ın NASH tedavisinde etkili bir seçenek olabileceğini, NAC’ın NASH tedavisinde daha az etkili olduğunu göstermektedir.
Evaluation of Therapeutic Effects of N-Acetylcysteine, Rosiglitazone and Etodolac in Rats with Nonalcoholic Steatohepatitis
Objective: The aim of this study was to assess the therapeutic effects of N-acetylcysteine (NAC), Rosiglitazone (RSG), and Etodolac (ETD) and their interactions with peroxisome proliferators-activated receptors-α (PPARα) in an experimental model of high-fat diet (HFD)-induced nonalcoholic steatohepatitis (NASH) in rats. Material and Method: Male Sprague-Dawley rats were randomly divided into five groups: Group 1 rats were fed with a standard diet (SD); Group 2 Rats were fed with high-fat diet (HFD); Group 3 Rats were fed with HFD and treated with NAC for 4 weeks; Group 4 rats were fed with HFD and treated with RSG for 4 weeks; Group 5 Rats were fed with HFD for twenty weeks and treated with ETD for 4 weeks. We evaluated the malondialdehyde (MDA) level, and the expression of PPAR-α in the liver in all groups. Results: In this study, it was observed that there was a significant increase in the expression of liver PPAR-α in the ETD group compared to the HFD group, and there was a significant decrease in the MDA level in the ETD group compared to the HFD group. We found a significant decrease in the expression of PPAR-α in the NAC group compared to the HFD group; and a significant decrease of the MDA level in the NAC group compared to the HFD group in our study. Conclusion: These findings indicate that ETD may be a good option for the treatment of NASH, and NAC is less effective for the treatment of NASH.
___
- 1. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: The State of the Disease. Gastroenterology 2020; 158: 1851-64.
- 2. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43: S99-S112.
- 3. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
- 4. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues. Hepatology 2010; 52: 2206-15.
- 5. Reddy JK. Nonalcoholic steatosis and steatohcpatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am J Physiol Gasterointest Liver Physiol 2001; 281: 1333-9.
- 6. Arsov T, Larter CZ, Nolan CJ et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice. Biochem Biophys Res Commun 2006; 342: 1152-9.
- 7. Svegliati-Baroni G, Candelaresi C, Saccomanno S et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169: 846-60.
- 8. Lingvay I. Raskin P, Szczepaniak LS. Effect of insulin-metformin HCl combination on hepatic steatosis in patients with type 2 diabetes. J Diabetes Complications 2007; 21: 137-42.
- 9. Jin GY, Bok SM, Han YM et al. Effectiveness of rosiglitazone on bleomycin-induced lung fibrosis: assessed by microcomputed tomography and pathologic scores. Eur J Radiol 2012; 8
- 10. Samah M, El-Aidy AER, Tawfik MK, Ewais MMS. Evaluation of the anti-fibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol 2012; 689: 186-93.
- 11. Honglei Zhang H, Lin You L, Min Zhao M. Rosiglitazone attenuates paraquat-induced lung fibrosis in rats in a ppar gamma-dependent manner. Eur J Pharmacol 2019; 851: 133-43.
- 12. Pastor A, Collado PS, Almar M, González-Gallego J. Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine. J Hepatol 1997; 27: 363-70.
- 13. Thong-Ngam D, Samuhasaneeto S, Kulaputana O, Klaikeaw N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 5127-32.
- 14. Liu W, Nakamura H, Tsujimura T et al. Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 2006; 97: 768-73.1: 1901-06.
- 15. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J General Virol 1997; 78: 1527-31.
- 16. Tsutsumi T, Suzuki T, Shimoike T et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937-46.
- 17. Kolluri SK, Corr M, James SY et al. The Renantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci USA 2005; 102: 2525-30.
- 18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions. Am J Gastroenterol 1999; 94: 2467-74.
- 19. Cochran, WG. Sampling Techniques. 2nd Ed., New York: John Wiley and Sons, Inc, 1963.
- 20. Zhao JS, Zhu FS, Liu S, Yang C-Q, Chen X-M. Pioglitazone Ameliorates Nonalcoholic Steatohepatitis by Down-Regulating Hepatic Nuclear Factor-Kappa B and cyclooxygenases-2 Expression in Rats. Chin Med J 2012; 125: 2316-21.